The procedure in brief

A ChondroFiller hip injection is a clinic-based outpatient appointment — nothing more involved than that. Patients are seen at either the Grantham or Sleaford clinic, treated under local anaesthetic, and go home the same day.

The pathway runs in four stages:

• Imaging review. Professor Paul Lee assesses your scans to map the cartilage damage and confirm the treatment is appropriate. On-site open MRI is available if you have no recent imaging.
• The injection. ChondroFiller is placed inside the hip joint under real-time ultrasound guidance — a needle, not an incision.
• Protected loading (weeks 1–6). A short period of reduced impact activity while the collagen scaffold settles in place.
• Gradual repair (months 3–6 onwards). The body's own cells migrate into the scaffold and begin building new tissue over the following months.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without a GP referral for hip assessment.

Why ultrasound guidance is essential for a hip injection

The hip joint sits considerably deeper beneath the skin than most peripheral joints — surrounded by layers of muscle, fat, and soft tissue before the capsule is reached. That depth makes freehand placement genuinely difficult: orthopaedic literature documents that up to 30% of intra-articular injections performed without image guidance miss the target entirely, meaning the injectate lands outside the joint space where it can do little good.

Real-time ultrasound solves this. The clinician tracks the needle tip live on screen as it passes through the soft tissue layers and enters the hip joint capsule, confirming intra-articular position before a single drop is released. It is a precision clinic technique rather than a surgical skill — no incision, no operating theatre, just accurate needle placement guided by imaging.

For a product like ChondroFiller, this accuracy is not merely preferable — it is functionally necessary. The collagen solution self-gels within minutes of entering a fluid joint environment. If the needle is even slightly off-target, the scaffold forms outside the joint space and cannot reach the worn cartilage surface it is intended to protect. Professor Paul Lee's expertise in image-guided hip procedures means that placement is confirmed visually before injection at every appointment.

How ChondroFiller works once it is inside the hip joint

ChondroFiller is not a painkiller, an anti-inflammatory, or a lubricant. It is an acellular injectable Type I collagen — a CE-marked Class III medical device — that acts as a temporary scaffold inside the joint space.

Once the collagen solution enters the warm, fluid environment of the hip joint, it self-gels within minutes, forming a three-dimensional matrix over the damaged cartilage surface. No dry joint bed is required; gelation happens naturally in the presence of joint fluid. The scaffold is then available to the body's own progenitor cells, which migrate in from the surrounding synovium, differentiate into chondrocytes, and progressively remodel the matrix into repair tissue. This process is known as acellular matrix-induced chondrogenesis — a scaffold that recruits your own cells to support the repair process, rather than delivering any active drug or foreign cells.

As that repair progresses, the collagen carrier gradually dissolves. It does not remain in the joint as a permanent implant.

Because the mechanism is biological rather than pharmacological, improvement develops over months, not days. Meaningful changes in pain and function typically emerge between three and six months after injection. A steroid injection suppresses inflammation in the short term; hyaluronic acid adds lubrication; ChondroFiller does neither — it promotes endogenous repair by giving the joint's own cells a structure to work within.

Step by step: what the appointment involves

The four-stage overview expands into five practical steps on the day itself — here is what each one involves.

1. Imaging review Professor Paul Lee begins by reviewing your existing MRI or X-ray to map the location and extent of cartilage damage and confirm the treatment plan. Where no recent scans are to hand, open MRI can be arranged on-site at the Grantham or Sleaford clinic so that the injection proceeds on a clear picture of the joint, not an estimate.

2. Skin preparation and local anaesthetic The skin overlying the hip injection site is cleaned and a small amount of local anaesthetic is applied. There is no theatre admission, no surgical gown, and no general anaesthetic — the procedure takes place in a standard clinic room.

3. Ultrasound-guided injection With the hip surface prepared, the ultrasound probe is positioned to provide a live view of the joint. The needle is advanced under continuous visualisation, intra-articular position is confirmed on screen, and ChondroFiller is delivered in liquid form into the joint space. Contact with the warm, fluid environment initiates gelation within minutes.

4. IV antibiotic cover Intravenous antibiotic cover is included in the procedure package as a standard infection precaution — a routine clinical step rather than a cause for concern.

5. Observation and discharge After a brief rest, the patient receives clear written guidance for the 4–6 week protected-loading period and leaves the same appointment. There is no overnight stay and no wound to manage.

The repair window: what to expect in the weeks and months after

Recovery divides into two clearly distinct phases, and understanding both helps manage expectations from the outset.

Weeks 1–6: protected loading During the first four to six weeks, the collagen scaffold is integrating and progenitor cells are beginning to migrate in. High-impact loading — running, heavy lifting, or sustained single-leg weight-bearing — is avoided during this window to give the gel time to stabilise within the joint. Day-to-day activities such as gentle walking are generally fine; the aim is to protect the scaffold, not to rest completely.

Months 3–6 and beyond: repair and functional improvement Meaningful functional change typically emerges between three and six months, as recruited cells progressively remodel the scaffold into repair tissue. Published outcome data — largely from knee studies — show approximately 30-point improvements in validated joint scores at 12 months. The biological mechanism in the hip is the same, and hip-specific outcome measures such as the modified Harris Hip Score follow a similar trajectory; however, large hip-specific randomised trial data remain limited, and this should be acknowledged when setting expectations.

ChondroFiller is not a pharmacological treatment, so most patients should not expect the rapid symptom change that sometimes follows a steroid injection. If early relief does occur, it is likely secondary to the cushioning effect of the gel rather than any anti-inflammatory action.

The six-week follow-up included in the procedure package provides a natural review point — a scheduled opportunity to check progress and address any questions before the main repair phase is fully under way.

Who this procedure is suitable for

The best-matched patients are those with a focal hip cartilage defect or early-to-moderate osteoarthritis confirmed on imaging — X-ray, MRI, or both. Where damage is clearly present but cartilage has not been fully lost, the collagen scaffold has a viable biological surface to work with; it needs surviving tissue around the defect to anchor the repair process.

Two situations represent absolute contraindications. End-stage arthritis — where imaging shows bone-on-bone contact and no functioning cartilage surface remains — removes the foundation the scaffold depends on. Active joint infection rules out any intra-articular injection until fully resolved.

Patients primarily seeking rapid, pharmacological-style symptom control are unlikely to find ChondroFiller a good fit. The biological repair timeline runs to months, and the treatment goal is tissue regeneration rather than acute pain suppression — a distinction already covered when the mechanism was described above.

Suitability is not assessed at the point of enquiry; it is confirmed by Professor Paul Lee following a structured imaging review. Open MRI is available on-site at the Grantham and Sleaford clinics for patients who arrive without recent scans. That assessment appointment exists precisely to establish whether the hip in question warrants the injection or would be better served by a different pathway — a determination only imaging can make reliably. An initial consultation with Professor Lee requires no GP referral.

1. [1] Intra-Articular Collagen Injections for Osteoarthritis: A Narrative Review. (2023). https://doi.org/10.3390/ijerph20054390 https://doi.org/10.3390/ijerph20054390